Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Restart Life SciencesNMLSF EV-to-OCF is -6.11 as of Aug. 10, 2026. The stock has 3 warning signs investors should review. Among 1,405 Biotechnology companies, Restart Life Sciences ranks better than 60.43% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Restart Life Sciences's Enterprise Value is $2.47 Mil.
Restart Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.40 Mil. Therefore, Restart Life Sciences's EV-to-OCF for today is -6.11.
The historical rank and industry rank for Restart Life Sciences's EV-to-OCF or its related term are showing as below:
NMLSF'
s EV-to-OCF Range Over the Past 10 Years
Min: -30.66 Med: -6.35 Max: -0.5
Current: -6.21
During the past 13 years, the highest EV-to-OCF of Restart Life Sciences was -0.50. The lowest was -30.66. And the median was -6.35.
NMLSF's EV-to-OCF is ranked better than 60.43% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs NMLSF: -6.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Restart Life Sciences (OTCPK:NMLSF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Restart Life Sciences's PE Ratio (TTM) for today is calculated as:
Restart Life Sciences's share price for today is $0.0697.
Restart Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Restart Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Restart Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Restart Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Restart Life Sciences's EV-to-OCF falls into.
Restart Life Sciences's current Enterprise Value is $2.47 Mil.
Restart Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Restart Life Sciences (NMLSF) has a EV-to-OCF of -6.11 as of Aug. 10, 2026. According to the industry distribution chart, Restart Life Sciences ranks #556 out of 1405 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Restart Life Sciences' EV-to-OCF too high?
Restart Life Sciences' current EV-to-OCF is -6.11. Based on the distribution chart, Restart Life Sciences ranks #556 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint.
How does Restart Life Sciences' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #556 out of 1405 companies for EV-to-OCF. This puts Restart Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Restart Life Sciences's current EV-to-OCF is -6.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (NMLSF) has a current EV-to-OCF of -6.11. The current EV-to-OCF is -6.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Restart Life Sciences (NMLSF), the current EV-to-OCF is -6.11 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMLSF has been successfully added to your 
